Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Loss Clear all
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Implementing Artificial Intelligence to Prevent Vision Loss From Diabetes

NCT07559292
View directory record Official record
Conditions
Vision Disorders, Diabetes
Interventions
AI, Usual Practice
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
22 Years and older
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 25, 2026, 5:24 AM EDT
Terminated Phase 4 Interventional

Functional Vision in TBI

NCT01214070
View directory record Official record
Conditions
Brain Injuries, Visually Impaired Persons
Interventions
Vision Restoration Therapy, NVT Eye Scanning Therapy, Eccentric Viewing Training, Sham
Other · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 79 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

NCT03927690
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 25, 2026, 5:24 AM EDT
Terminated Phase 1 Interventional

Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia

NCT04784390
View directory record Official record
Conditions
Amblyopia
Interventions
Binocular video games, Patching of the sound eye
Device
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
4 Years to 12 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Gainesville, Florida • Maitland, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 25, 2026, 5:24 AM EDT
Withdrawn Phase 3 Interventional

Epinephrine in Irrigation Fluid for Visualization During Ankle Surgery

NCT06264596
View directory record Official record
Conditions
Intraoperative Bleeding
Interventions
Epinephrine, Normal Saline irrigation fluid
Drug · Procedure
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

NCT04005352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Not applicable Interventional

Feasibility Tests for Various Prism Configurations for Visual Field Loss

NCT04424979
View directory record Official record
Conditions
Hemianopia, Homonymous, Tunnel Vision, Visual Field Defect, Peripheral, Visual Field Constriction Bilateral, Visual Field Defect Homonymous Bilateral
Interventions
High power prisms
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
7 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

NCT01703559
View directory record Official record
Conditions
Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Not applicable Interventional

Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration

NCT01653184
View directory record Official record
Conditions
Macular Degeneration
Interventions
Omega-3 fatty acid
Dietary Supplement
Lead sponsor
Wills Eye
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Cherry Hill, New Jersey • Bethlehem, Pennsylvania • Huntingdon Valley, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 25, 2026, 5:24 AM EDT
Active, not recruiting Phase 3 Interventional

Oral N-acetylcysteine for Retinitis Pigmentosa

NCT05537220
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
24
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 25, 2026, 5:24 AM EDT
Not yet recruiting Phase 4 Interventional

Iopidine to Decrease Intraocular Pressure Rise After Injections

NCT07891910
View directory record Official record
Conditions
Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
Interventions
Apraclonidine 1.0% ophthalmic solution
Drug
Lead sponsor
Retina Consultants of Delmarva
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Easton, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 25, 2026, 5:24 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss

NCT06670989
View directory record Official record
Conditions
Central Vision Loss From Macular Diseases
Interventions
Fixation training
Behavioral
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 25, 2026, 5:24 AM EDT
Terminated No phase listed Observational

Effects of Nitrous Oxide on Intraocular Pressure

NCT00696189
View directory record Official record
Conditions
Post Operative Visual Loss
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

Effect of Ruboxistaurin on Clinically Significant Macular Edema

NCT00133952
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ruboxistaurin, Placebo
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Phoenix, Arizona • Artesia, California • Newark, Delaware + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 25, 2026, 5:24 AM EDT
Completed No phase listed Observational

Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma

NCT04458935
View directory record Official record
Conditions
Retinal Hemangioblastoma, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
7 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Low Vision Intervention Trial II (LOVIT II)

NCT00958360
View directory record Official record
Conditions
Central Vision Loss From Macular Diseases
Interventions
Interdisciplinary Low Vision Service, Basic Low Vision Service
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Hines, Illinois • Baltimore, Maryland • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Not applicable Interventional

Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell

NCT04710394
View directory record Official record
Conditions
Anosmia, Covid19, Ageusia, Hyposmia, Hypogeusia, SARS-CoV-2 Infection, COVID-19 Pandemic
Interventions
Smell Training
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

NCT06349759
View directory record Official record
Conditions
Mesopic Vision, Night Vision Loss
Interventions
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, Placebo
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
25
States / cities
Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Phase 1 Interventional

Acupuncture for the Treatment of Vision Loss Due to Retinitis Pigmentosa

NCT01604356
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Electro-acupuncture
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 25, 2026, 5:24 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

NCT05176717
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
QR-421a, Sham-procedure
Drug · Other
Lead sponsor
Laboratoires Thea
Industry
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 25, 2026, 5:24 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Measuring Relative Afferent Pupillary Defect

NCT05799066
View directory record Official record
Conditions
Relative Afferent Pupil Defect (RAPD)
Interventions
Swinging Light test, Virtual Reality Head-Mounted Display (VR HMD)
Diagnostic Test
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 85 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 25, 2026, 5:24 AM EDT
Completed Not applicable Interventional Results available

Laparoscopic Sleeve Gastrectomy With Endoscopic Visualization

NCT00911989
View directory record Official record
Conditions
Morbid Obesity
Interventions
NOTES toolbox
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 25, 2026, 5:24 AM EDT